The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
Scientists at the Massachusetts General Hospital (MGH) have initiated a phase 1 clinical trial to reverse type 1 diabetes.
A novel aerosol version of the most common tuberculosis (TB) vaccine, administered directly to the lungs as an oral mist, offers significantly better protection against the disease in experimental animals than a comparable dose of the traditional injected vaccine, researchers report this week in the Proceedings of the National Academy of Sciences.
The BCG vaccine, which aims to prevent tuberculosis among children in developing countries, might be causing illness and death among some HIV-positive infants, researchers said on Friday, the Los Angeles Times reports.
Experts in South Africa say a vaccine which was meant to protect children in developing countries from tuberculosis (TB)may in fact be killing them.
Using a novel approach, researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a prototype vaccine against tuberculosis (TB) that works better in animal models than the only TB vaccine now available.
Initial trials of a new tuberculosis (TB) vaccine mean the drug will now progress to phase II trials.
New tuberculosis (TB) vaccines in development have the potential to provide protection against all strains of TB, including multidrug-resistant (MDR) and extensively drug- resistant (XDR) TB, Dr. Jerald C.
Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB) vaccine, providing a new low-cost and scaleable technique that offers needle-free delivery and greater stability at room temperature than existing methods.
A key aspect of how the body kicks the immune system into action against tuberculosis is revealed in research published today.
A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization.
There are about 10 million cases of TB globally each year and 1 in 3 people are infected with the TB bacterium. BCG is the most widely used vaccine worldwide, but its mechanism of protection is poorly understood. It is thought to prevent progression of infection to active TB but whether it protects against the acquisition of infection itself has not been investigated in humans.
From autumn 2005, the long running routine programme to vaccinate school children against tuberculosis with BCG vaccine will stop. This decision brings the UK into line with much of the rest of the world and is well justified, writes Professor Paul Fine in the British Medical Journal (BMJ).
Max Planck researchers have uncovered the mechanism by which the new genetically engineered tuberculosis vaccine functions.
Tuberculosis remains a major global health threat. Although more than 3 billion doses of the BCG vaccine have been administered to fight tuberculosis, the ability of the BCG vaccine to protect adults is very limited, as is its efficacy against newly emerging isolates.
The Tuberculin skin test, used to detect latent Mycobacterium tuberculosis infection, has many drawbacks and a new diagnostic test for latent tuberculosis (QuantiFERON®-TB) has recently been introduced.
Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.